Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Nucala Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The expansion observed during the historical timeframe has been driven by a higher incidence of severe eosinophilic asthma, greater awareness and identification of eosinophilic conditions, the broadening of protocols for biological therapies, enhanced diagnostic methods for measuring eosinophil counts, and the increasing tendency of specialists to prescribe these treatments.
Growth in the forecast period stems from expanding use in other eosinophilic conditions, a rising need for tailored respiratory biologics, progress in monoclonal antibody development, wider international reimbursement policies, and greater uptake of home-based treatment methods. Key trends shaping this period include greater reliance on specific biologic asthma treatments, increasing application of IL-5 inhibitors in long-term illnesses, broader integration of precision medicine into respiratory management, heightened emphasis on sustained disease management, and refined approaches to patient categorization.
Download A Free Sample Report For Comprehensive Market Insights:
Nucala Market Development Factors: Which Trends Are Supporting Demand?
The rising occurrence of asthma is anticipated to boost the expansion of the nucala market in the upcoming period. Asthma is a long-term respiratory disorder marked by inflammation and constriction of the airways, causing signs like wheezing, coughing, chest tightness, and breathlessness, frequently set off by allergens or physical exertion. This growth in asthma cases is linked to elements including environmental pollution, allergens, evolving lifestyles, urbanization, and hereditary factors. Nucala helps control asthma by specifically blocking interleukin-5 (IL-5), a crucial protein that promotes the development and activation of eosinophils—white blood cells that play a role in airway inflammation in asthma—thus decreasing symptoms and the frequency of asthma attacks. As an example, in February 2023, based on data from NHS England, a UK government agency, 5.4 million individuals in the UK receive care for asthma, with roughly 160,000 new diagnoses each year, and work-related asthma constitutes 9-15% of cases that emerge in adulthood. Hence, the growing prevalence of asthma is fueling growth in the nucala market.
The heightened frequency of eosinophilic disorders is set to drive the nucala market forward in the coming years. Eosinophilic disorders are a collection of medical issues where an excessive production and buildup of eosinophils, a kind of white blood cell, occurs in different tissues, causing inflammation and possible harm. This rise in eosinophilic disorders is due to factors like increasing environmental allergens, shifts in eating patterns, genetic tendencies, and greater awareness leading to better detection rates. Nucala (mepolizumab) addresses eosinophilic disorders by acting on and impeding interleukin-5 (IL-5), a cytokine essential for the growth and persistence of eosinophils, thereby lowering eosinophil counts and easing related symptoms. For example, in December 2023, as reported by PubMed, a US-based government-run non-profit online database, the global combined incidence and prevalence of eosinophilic esophagitis (EoE) stood at 5.31 cases per 100,000 person-years. Consequently, the increasing prevalence of eosinophilic disorders is propelling growth in the nucala market.
Nucala Market Segment Outlook: Which Categories Are Expanding The Fastest?
The nucala market covered in this report is segmented –
1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Chronic Obstructive Pulmonary Disease (COPD), Other Eosinophilic Disorders
2) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
3) By End User: Hospitals, Clinics, Home Care Settings
Nucala Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the Nucala market are placing emphasis on creating advanced solutions, like ready-to-use injectable formats, to address the growing need for patient ease-of-use and better medication adherence. A ready-to-use injectable is a pre-made pharmaceutical preparation that does not require any additional dilution or mixing before it is administered. As an example, GlaxoSmithKline Plc, a pharmaceutical firm from the UK, secured approval from the US FDA in May 2025 for Nucala (mepolizumab) as a treatment for adults with chronic obstructive pulmonary disease (COPD) that exhibits an eosinophilic phenotype. This expansion of the drug’s indication makes targeted therapy available for COPD patients who face significant unmet needs, driven by encouraging outcomes from the MATINEE and METREX Phase III trials.
Nucala Market Key Companies And Competitive Benchmarking
Major companies operating in the nucala market are GlaxoSmithKline plc
Access The Complete Nucala Market Report:
Nucala Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the nucala market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucala market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model